Biotechs' new, very different approach to weight loss drugs

Also: Reversing progress, stroke rates are rising, especially in working-age adults

May 23, 2024 Check out STAT+

Sponsored By

David J. Phillip/AP Fresh scrutiny of post-Covid spending reignites yearslong tension over emergency stockpiles The controversy comes at a pivotal time for the health department's efforts to justify an expanded role for the office known as ASPR. By Sarah Owermohle STAT+ | Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again, and other thoughts Plus, some other thoughts on the company's decision to sell Royalty Pharma a share of its heart drug for up to $575 million. By Adam Feuerstein Reversing progress, stroke rates are rising, especially in working-age adults Uncontrolled hypertension, more obesity, unequal medical access, and the opioid epidemic are all seen as causes of rising stroke rates. By Elizabeth Cooney Marian F. Moratinos for STAT STAT+ | Biotechs turn to gene silencing for obesity drugs that can last longer than Wegovy As shown in STAT's Obesity Drug Tracker, Regeneron and others are using RNA interference to target genetics, rather than hormones like GLP-1. By Allison DeAngelis and Elaine Chen STAT+ | Setting the table: What to expect at this year's ASCO meeting Merus is the buzziest biotech of the ASCO runup, and why Immunocore is Adam's No. 2 biotech abstract pick of the meeting. By Adam Feuerstein In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu Today's biotech news update includes mRNA vaccine makers on bird flu, Gilead's coronavirus antiviral, and Click's GLP-1 experiment. By Elaine Chen Allen G. Breed/AP Louisiana legislature approves bill classifying abortion pills as controlled dangerous substances State lawmakers Thursday passed the bill to reclassify mifepristone and misoprostol, and Republican Gov. Jeff Landry is expected to sign it into law. By Associated Press

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser